Citations

Clear

16280 citation(s) found for "Yu, David".

AAV9-mediated KCNH2 suppression-replacement gene therapy in a transgenic rabbit model of type 1 short QT syndrome
Nimani, Saranda , Bains, Sahej , Alerni, Nicolò , Ördög, Balázs , Horváth, András , Matas, Lluis , Louradour, Julien , Giammarino, Lucilla , Tester, David J. , Beslac, Olgica, López, Rubén , Meier, Stefan , Christoforou, Nicolas , Barbieri, Miriam , Vashanthakumar, Varjany, Perez‐Feliz, Stefanie , Casalta, L.G. Garcia, Kim, C.S. John, Zhou, Wei , Ye, Dan , Jurgensen, Jacqulyn, Bego, Mariana G. , Keyes, Lisa R., Owens, Jane , Pinkstaff, Jason, Zehender, Manfred, Brunner, Michael, Heijman, Jordi , Casoni, Daniela , Brooks, Gabriel , Odening, Katja E. , Egle, Manuel , Barbieri, Miriam , Christoph, Jan , Brunner, Michael , Heijman, Jordi , Praz, Fabien , Haeberlin, Andreas , Ackerman, Michael J , Odening, Katja E , Bains, Sahej , Vashanthakumar, Varjany, Parodi, Chiara, Barry, Michael A. , Praz, Fabien , Ackerman, Michael

Mayo Clinic

European Heart Journal | August 15, 2025 | Volume: 47 | Issue: 2 | Pages: 199-213

10.1093/eurheartj/ehaf660 | PMID 40884219 Get It

Abstract Background and Aims Type 1 short QT syndrome (SQT1) is a genetic channelopathy caused by gain-of-function variants in KCNH2, resulting in shortened cardiac repolarization and QT intervals, which predispose patients to ventricular arrhythmias and sudden cardiac death. This study aimed to investigate the therapeutic efficacy of KCNH2-specific suppression-and-replacement (KCNH2-SupRep) gene therapy in a transgenic rabbit model of SQT1. Methods KCNH2-SupRep was developed by combining a KCNH2-shRNA with its corresponding shRNA-immune KCNH2-cDNA into an AAV9 vector, delivered directly into the aortic root (1 × 1010 vg/kg). Therapeutic efficacy was evaluated in vivo by electrocardiogram, ex vivo by optical mapping, and at cellular levels by patch-clamp, calcium imaging, and qPCR in ventricular cardiomyocytes (VCMs). Results In vivo, KCNH2-SupRep normalized the heart rate-corrected QT interval (QTc) in SQT1 rabbits, without affecting repolarization heterogeneity. Ex vivo, KCNH2-SupRep corrected the action potential duration (APD90) and resolved the increased apicobasal APD90 heterogeneity observed in untreated (UT)-SQT1 hearts, supporting an antiarrhythmic effect, which was further validated by reduced re-entry formation in silico. At cellular levels, KCNH2-SupRep prolonged APD90 in VCMs from SupRep-SQT1 rabbits closer to wildtype levels compared with UT- and sham-SQT1. Additionally, KCNH2-SupRep restored the cellular surrogate of the electro-mechanical window and normalized IKr in nearly 50% of VCMs, in line with a 50%–60% suppression of the mutant KCNH2 transcript. Conclusions This proof-of-concept study is the first to demonstrate the efficacy of gene therapy for SQT1 in a medium-sized animal model. KCNH2-SupRep gene therapy successfully corrected the pathologic phenotype in vivo, ex vivo, and at cellular levels in transgenic SQT1 rabbits.
New comorbidity index associated with survival after chimeric antigen receptor T-cell therapy for large B-cell lymphoma
Greenbaum, Uri , Hashmi, Hamza , Elsawy, Mahmoud , Kim, Soyoung , Moskop, Amy , Oloyede, Temitope, Awan, Farrukh T. , Bachanová, Veronika , Badar, Talha , Bar, Merav , Barba, Pere , Cashen, Amanda F. , Ganguly, Siddhartha , Kittai, Adam S. , Lulla, Premal , Mead, Elena, Geethakumari, Praveen Ramakrishnan , Saber, Wael , Strouse, Christopher , Valluripalli, Anusha, Wudhikarn, Kitsada , Pasquini, Marcelo C. , Dholaria, Bhagirathbhai R , Farooq, Umar , Hematti, Peiman , Hill, LaQuisa C , Jain, Michael D , Jain, Tania , Lulla, Premal D , McGuirk, Joseph , Mussetti, Alberto , Nishihori, Taiga , Olson, Amanda L , Perales, Miguel-Angel , Riedell, Peter A , Shouval, Roni , Magalhaes-Silverman, Margarida , Pasquini, Marcelo , Ahmed, Sairah , Sorror, Mohamed , Bachanova, Veronika , Badar, Talha , Strouse, Christopher S , Awan, Farrukh T , Kim, Soyoung , Moskop, Amy , Beitinjaneh, Amer , Dholaria, Bhagirathbhai , Foglesong, Jessica , Hematti, Peiman , Hill, LaQuisa C. , Jain, Michael D. , Jain, Tania , Kebriaei, Partow , Locke, Frederick L. , McGuirk, Joseph P. , Mussetti, Alberto , Nishihori, Taiga , Pennisi, Martina , Perales, Miguel‐Angel , Riedell, Peter A. , Shpall, Elizabeth J. , Magalhaes‐Silverman, Margarida , Turtle, Cameron J. , Vallurupalli, Anusha , Ahmed, Sairah , Sorror, Mohamed L.

Mayo Clinic

Blood Advances | August 14, 2025 | Volume: 10 | Issue: 1 | Pages: 217-227

10.1182/bloodadvances.2024015599 | PMID 40811818 Get It

Abstract The cumulative impact of baseline comorbidities on outcomes of chimeric antigen receptor T-cell (CAR-T) therapy is not well established. Therefore, we developed and validated a Cellular Therapy Comorbidity Index (CT-CI) to predict outcomes following CD19-directed CAR-T therapy for large B-cell lymphoma (LBCL). Patients aged 18 or older receiving commercial CAR-T therapy for LBCL during 2017 to 2020 were selected from the Center for International Blood and Marrow Transplant Research registry. Patients were randomly assigned to training or validation cohorts. Comorbidities given weighted scores comprised the CT-CI, which was then validated for overall survival (OS) prognostication. A total of 1916 patients from 97 medical centers were included, with a median age of 64 years (19-91 years). About 70% of patients had comorbidities, such as cardiac disease (12%); diabetes (14%); hepatic dysfunction (mild, 8%; moderate to severe, 2%); psychiatric disturbance (18%); and pulmonary dysfunction (moderate, 15%; severe, 12%). The CT-CI was calculated, stratified patients in 3 categories, and was associated with increased mortality. Patients with higher CT-CI scores had worse OS (CT-CI 1: hazard ratio [HR], 1.37 [95% confidence interval [CI], 1.16-1.62; P< .001]; CT-CI 2: HR, 1.49 [95% CI, 1.17-1.89; P = .001]; CT-CI ≥ 3: HR, 2.55 [95% CI, 1.90-3.42; P< .001]). Higher CT-CI scores predicted treatment-related mortality and relapse. There was no correlation between the CT-CI score and CAR-T–related toxicities. The novel CT-CI score stratifies the effect of patient comorbidities on survival after CAR-T therapy and can be used for clinical decision-making and treatment selection in high-risk populations. However, comorbidities and fear of increased toxicity should not preclude patients from this effective therapy.
Plasma proteomic analysis identifies proteins and pathways related to Alzheimer's risk
Huang, Yen-Ning , Liu, Shiwei , Park, Tamina, Chaudhuri, Soumilee , Carrasquillo, Minerva M. , Ertekin‐Taner, Nilüfer , Bice, Paula J. , Blennow, Kaj , Russ, Kristen A., Dage, Jeffrey L. , Brosch, Jared R. , Farlow, Martin R. , Clark, David G., Mathew, Sunu , Unverzagt, Frederick W. , Gao, Sujuan , Apostolova, Liana G. , Foroud, Tatiana, Risacher, Shannon L. , Nho, Kwangsik, Kuchenbecker, Lindsey A. , Dage, Jeffrey L , Carrasquillo, Minerva M. , Zetterberg, Henrik , Nudelman, Kelly , Cruchaga, Carlos , Wang, Sophia , Wilcock, Donna M. , Saykin, Andrew J.

Mayo Clinic

Alzheimer's & Dementia | August 14, 2025 | Volume: 21 | Issue: 8 | Pages: No page available

10.1002/alz.70579 | PMID 40810263 Get It

Abstract INTRODUCTION We investigated associations of plasma proteins with blood‐based amyloid/tau/neurodegeneration/inflammation (A/T/N/I) biomarkers for Alzheimer's disease (AD). METHODS Plasma proteomics and clinical data from the Indiana AD Research Center ( N = 498) were used. Association analysis of plasma proteins with blood A/T/N/I biomarkers as well as diagnosis was performed, followed by replication in an independent cohort ( N = 323), network analysis, pathway enrichment, and machine learning classification to identify proteins and pathways related to AD risk. RESULTS We identified 35 proteins associated with AD, 20 of which were replicated in the independent cohort. We identified 150, 448, and 219 proteins associated with T/N/I biomarkers, respectively, revealing biomarker‐specific pathways. Network analysis identified two modules associated with T/N/I biomarkers, preserved in cerebrospinal fluid (CSF), and their enriched pathways. The classification model of proteins effectively differentiated AD (area under the curve [AUC] = 0.930). CONCLUSION Our findings suggest dysregulated plasma proteins and pathways in AD, enhancing our understanding of molecular mechanisms and diagnostic strategies for AD. Highlights Plasma proteins were identified as being associated with Alzheimer's disease (AD) and plasma biomarkers. The identified proteins were replicated in both plasma and cerebrospinal fluid (CSF) proteomics. The identified proteins were associated with AD biomarker‐specific pathways. The identified proteins improved the performance of the AD classification. Protein network analysis identified network modules and their enriched pathways.
3D magnetization‐prepared rapid gradient echo with a RF saturation band on a compact 3T scanner
Speltz, Lydia J. Bardwell , In, Myung‐Ho , Trzasko, Joshua D. , Halverson, Maria, Gray, Erin M. , Shu, Yunhong , Bardwell Speltz, Lydia J , Gray, Erin, In, Myung-Ho , Kang, Daehun , Campeau, Norbert G. , Huston, John , Warner, David O. , Bernstein, Matt A.

Mayo Clinic

Medical Physics | August 14, 2025 | Volume: 52 | Issue: 8 | Pages: No page available

10.1002/mp.18039 | PMID 40804787 Get It

Abstract Background Flow‐related ghost artifact from a 3D Magnetization Prepared Rapid Gradient Echo (MPRAGE) sequence results from unsaturated magnetization of incoming arterial flow. This is especially common on MR scanners equipped with smaller radiofrequency (RF) transmit coils. A high‐performance compact 3T (C3T) scanner features a smaller RF‐transmit coil (inner diameter 37 cm, length 40 cm), leading to a rapid fall‐off of the B1 field below the neck. This configuration results in more intense flow‐related ghost artifacts, especially in younger patients. Purpose The C3T scanner's smaller RF‐transmit coil provides RF field coverage over the brain region, causing bright in‐flow arterial signals and flow‐related artifacts in the conventional 3D‐MPRAGE scans. The purpose of this study is to suppress these artifacts by adding a RF saturation band (RFSB) pulses to the 3D‐MPRAGE sequence. Methods The RFSB was added to the 3D‐MPRAGE sequence as a preparation pulse option. To test the effectiveness, 37 subjects were scanned on the C3T under an IRB‐approved protocol using 3D‐MPRAGE with and without RFSB. Ten of those subjects underwent repeated scans with and without RFSB to evaluate test‐retest reliability. A consensus evaluation by two neuroradiologists was performed on all data to compare signal to noise ratio, image contrast, presence of artifacts, and diagnostic confidence. Quantitative analysis included calculating test‐retest differences by image subtraction and evaluating the variance in flow‐artifact‐induced image intensity between the scans with and without RFSB. Additionally, one subject was scanned on a whole‐body 3T scanner using a transmit/receive (T/R) head coil to demonstrate the method's applicability across different MRI platforms as a proof of concept. Results The Wilcoxon signed‐rank test of the neuroradiologist evaluations showed a significant reduction in artifacts and an improvement in diagnostic confidence in the posterior fossa region with and without RFSB ( p < 0.0001). Test–retest analysis showed that adding RFSB significantly reduced image intensity variability in the cerebellum, even among subjects without visible flow artifacts. The normalized difference decreased from 8.71% to 6.41% ( p = 0.0059), suggesting improved image reliability in regions prone to flow‐related artifacts. Additionally, similar findings were observed in scans on a whole‐body 3T with a T/R head coil, demonstrating the broader applicability of this method. Conclusion Incorporating RFSB into 3D‐MPRAGE scans effectively reduces flow‐related ghost artifact on the C3T scanner, improving image quality and diagnostic confidence. These findings suggest that the proposed method could be widely implemented across MRI systems utilizing a smaller RF‐transmit coil.
Somatic CRISPR tumorigenesis and multiomic analysis reveal a pentose phosphate pathway disruption vulnerability in MPNSTs
McGivney, Gavin R. , Brockman, Qierra R. , Borcherding, Nicholas , Scherer, Amanda , Rauckhorst, Adam J. , Gutierrez, Wade R. , Solst, Shane R. , Heer, Collin D. , Warrier, Akshaya , Floyd, Warren , Kirsch, David G. , Knepper-Adrian, Vickie, Laverty, Emily A. , Roughton, Grace A. , Spitz, Douglas R. , Taylor, Eric B. , Dodd, Rebecca D. , Knepper-Adrian, Vickie L , Borcherding, Nicholas , Spitz, Douglas R

Mayo Clinic

Science Advances | August 13, 2025 | Volume: 11 | Issue: 33 | Pages: No page available

10.1126/sciadv.adu2906 | PMID 40802750 Get It

Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive and chemo-resistant sarcomas with poor survival rates. Loss of CDKN2A or P53 following NF1 disruption is a key event in MPNST development. Here, we used CRISPR-Cas9 somatic tumorigenesis in mice to identify transcriptomic and metabolomic features distinguishing CDKN2A - versus P53 -deleted MPNSTs. Convergent, multiomic analyses revealed that CDKN2A -deleted MPNSTs are especially dependent on the pentose phosphate pathway (PPP) and NADPH metabolism for growth and viability. Disruption of glucose-6-phosphate dehydrogenase (G6PD), the PPP rate-limiting enzyme, slowed CDKN2A -deleted MPNST growth and sensitized MPNSTs to standard-of-care chemotherapy. Knockdown of the redox-regulated transcription factor NRF2 slowed MPNST growth and decreased G6PD transcription. Analysis of patient MPNSTs identified a NRF2 gene signature correlating with tumor transformation. Furthermore, G6PD and NRF2 expression in PanCancer TCGA samples correlates with patient survival. This work identifies NRF2-PPP dependency as a targetable vulnerability in these difficult-to-treat MPNSTs, particularly in the NF1/CDKN2A -deleted majority.
Prognostication Following Transcatheter Edge-to-Edge Mitral Valve Repair Using Combined Echocardiography-Derived Velocity Time Integral Ratio and Artificial Intelligence Applied to Electrocardiogram
Bismee, Nadera N. , Scalia, Isabel G. , Abbas, Mohammed Tiseer , Farina, Juan M. , Pereyra, Milagros , Ali, Nima Baba , Esfahani, Sogol Attaripour , Sheashaa, Hesham, Ibrahim, Omar , Abdelfattah, Fatmaelzahraa , Fortuin, F. David , Lester, Steven J., Sweeney, John P., Arsanjani, Reza , Esfahani, Shadi A. , Pereyra, Milagros , Baba Ali, Nima , Javadi, Niloofar , Sheashaa, Hesham , Ibrahim, Omar H , Abdelfattah, Fatmaelzahraa , Arsanjani, Reza , Farina, Juan M , Scalia, Isabel G , Abbas, Mohammed Tiseer , Awad, Kamal

Mayo Clinic

Journal of Personalized Medicine | August 13, 2025 | Volume: 15 | Issue: 8 | Pages: 371

10.3390/jpm15080371 | PMID 40863433 Get It

Introduction: Mitral valve transcatheter edge-to-edge repair (M-TEER) has emerged as a minimally invasive option for high-risk surgical candidates with severe and symptomatic mitral regurgitation (MR), but post-procedure residual mitral valve (MV) dysfunction remains a significant concern. This study evaluates the clinical utility of combining artificial intelligence applied to electrocardiograms (ECG-AI) for diastolic dysfunction (DD) grading and the echocardiography-derived velocity time integral of the MV and left ventricular outflow tract ratio (VTIMV/LVOT) in predicting prognosis in patients post-M-TEER. Methods: A retrospective analysis of patients who underwent M-TEER between 2014 and 2021 was conducted. Patients were categorized based on VTIMV/LVOT and ECG-AI scores into three groups: both normal parameters, either abnormal parameter, or both abnormal parameters to compare outcomes (mortality, major adverse cardiovascular events [MACE], and the need for subsequent MV reintervention) using Kaplan–Meier analysis, multivariable Cox regression models, and net reclassification improvement. Results: Overall, 250 patients were included; the median age was 79.5 (IQR: 73.1, 84.6) and 66.4% were male. The combined abnormal VTIMV/LVOT (≥2.5) and ECG-AI score for DD (>1) was associated with higher risk of one-year mortality (adjusted HR: 4.56 [1.04–19.89], p = 0.044) and MACE (adjusted HR: 3.72 [1.09–12.72], p = 0.037) compared to patients with both normal parameters. Conclusions: This study highlights the potential additive value of integrating VTIMV/LVOT and ECG-AI scores as a prognostic tool for a personalized approach to the post-operative evaluation and risk stratification in M-TEER patients.
The Association of Bone Stress Injuries With Body Mass Index Percentile Drop and Eating Disorder Diagnoses in Adolescent Athletes
Potts, A. , Soma, David , Sim, Leslie , Henz, Roland, Hickman, Joel , Potts, Audrey, Lebow, Jocelyn

Mayo Clinic

Journal of Athletic Training | August 13, 2025 | Volume: 61 | Issue: 3 | Pages: 239-245

10.4085/1062-6050-0160.25 | PMID 41816311 Get It

Context Adolescence is a critical period for bone development. Due to an elevated risk for low body mass index (BMI) and/or low energy availability, certain adolescent athletes are at increased risk of bone stress injury (BSI) and eating disorders (EDs). Despite this risk, the incidence of EDs in patients with BSI is unclear. Objective To compare the incidence of a premorbid drop in BMI percentile in a sample of adolescent athletes diagnosed with a BSI between 2005 and 2016. We also evaluated the relative risk of developing an ED for this sample, compared with a sex-matched, age-matched (±6 months), and time-matched (±2 years) sample of active adolescents with knee pain. Design Retrospective cohort study. Setting Data collected through the Rochester Epidemiology Project. Patients or Other Participants One hundred eighty-seven adolescent (aged 13–18) athletes with BSI and 187 active adolescents with knee pain. Main Outcome Measure(s) Conditional logistic regression was used to assess whether premorbid weight loss was a risk factor for BSI. A stratified log-rank test was used to evaluate the association between ED diagnosis and case-control status up to 5 years postinjury. Results Patients with a BSI had 1.53 times the odds of premorbid BMI percentile drop compared with controls (95% CI = 0.83, 2.12; P = .17). A total of 14 patients with a BSI had ED diagnoses after injury compared with 8 controls ( P = .13). Patients from weight-based or aesthetic sports had 1.93 times the odds of a BSI compared with controls (95% CI = 1.23, 3.02; P = .0040). The Kaplan-Meier estimates indicate that the case group had a greater risk of ED diagnosis. Conclusions Results suggest a trend toward a greater drop in BMI percentile and increased frequency of ED diagnoses in the BSI group compared with controls. The documented co-occurrence of weight loss, stress fractures, and EDs in adolescent athletes should inform guidelines for screening and treatment of adolescent athletes with BSIs.
Body mass index and subsequent fracture risk: a meta-analysis to update FRAX
Harvey, Nicholas C. , Johansson, Helena, McCloskey, Eugène , Liu, Enwu , Åkesson, Kristina , Anderson, Fred, Bager, Cecilie L. , Christiansen, Claus, Cooper, Cyrus , Crandall, Carolyn , Cummings, Steven R. , Dawson‐Hughes, Bess , Eisman, John A. , Fujita, Yuki , Fujiwara, Saeko , Glüer, Claus‐Christian , Guðnason, Vilmundur , Hall, Jill, Huisman, Martijn , Iki, Masayuki , Ish‐Shalom, Sophia, Koromani, Fjorda , Kröger, Heikki , Esfahani, Zahra , McGuigan, Fiona E. , Mellström, Dan, Merlijn, Thomas , Nguyen, Tuan V., Ohlsson, Claes , Pasco, Julie A. , Rivadeneira, Fernando, Schei, Berit , Shiroma, Eric J. , Siggeirsdóttir, Kristín , Swart, Karin M. A. , Tamaki, Junko , Staa, Tjeerd van , Wareham, Nicholas J, Yoshimura, Noriko , Zwart, Marta , Kanis, John A, McCloskey, Eugene V , Åkesson, Kristina E , Biver, Emmanuel , Center, Jacqueline R , Cooper, Cyrus , Crandall, Carolyn J , Dawson-Hughes, Bess , Dufour, Alyssa B , Eisman, John A , Ferrari, Serge , Hans, Didier B. , Iki, Masayuki , Karlsson, Magnus K , Khosla, Sundeep , Kiel, Douglas P , Koromani, Fjorda , Kwok, Timothy , Lamy, Olivier , Larijani, Bagher , McGuigan, Fiona E A , Merlijn, Thomas , Ohlsson, Claes , Orwoll, Eric S , Simonsick, Eleanor Marie , Sund, Reijo , Szulc, Pawel , Tamaki, Junko , Wright, Nicole C , Zillikens, M. Carola , Lorentzon, Mattias , Leslie, William D , Azagra, Rafael , Beaudart, Charlotte , Bischoff‐Ferrari, Heike A. , Biver, Emmanuel , Bruyère, Olivier , Cauley, Jane A. , Chapurlat, Roland D , Silva, José António Pereira da , Díez‐Pérez, Adolfo , Elders, Petra J. M. , Ferrari, Serge , Goldshtein, Inbal , Goltzman, David , Hall, Jill, Hoff, Mari , Hollick, Rosemary J , Jones, Graeme , Khosla, Sundeep , Kiel, Douglas P. , Koh, Woon‐Puay , Kotowicz, Mark A. , Langhammer, Arnulf , Lippuner, Kurt , Nordström, Anna , Nordström, Peter , O’Neill, Terence W , Obermayer-Pietsch, Barbara Maria , Orwoll, Eric , Rivadeneira, Fernando , Schott, Anne‐Marie , Sornay‐Rendu, Elisabeth , Szulc, Paweł , Torgerson, David John , Schoor, Natasja M. van , Vila, Joan , Vandenput, Liesbeth , Lorentzon, Mattias , Leslie, William D. , Kanis, John A.

Mayo Clinic

Journal of Bone and Mineral Research | August 12, 2025 | Volume: 40 | Issue: 10 | Pages: 1144-1155

10.1093/jbmr/zjaf091 | PMID 40795319 Get It

Abstract The aim of this international meta-analysis was to quantify the predictive value of BMI for incident fracture and relationship of this risk with age, sex, follow-up time, and BMD. A total of 1 667 922 men and women from 32 countries (63 cohorts), followed for a total of 16.0 million person-years were studied. 293 325 had FN BMD measured (2.2 million person-years follow-up). An extended Poisson model in each cohort was used to investigate relationships between WHO-defined BMI categories (Underweight: &lt;18.5 kg/m2; Normal: 18.5-24.9 kg/m2; Overweight: 25.0-29.9 kg/m2; Obese I: 30.0-34.9 kg/m2; Obese II: ≥35.0 kg/m2) and risk of incident osteoporotic, major osteoporotic and hip fracture (HF). Inverse-variance weighted β-coefficients were used to merge the cohort-specific results. For the subset with BMD available, in models adjusted for age and follow-up time, the hazard ratio (95% CI) for HF comparing underweight with normal weight was 2.35 (2.10-2.60) in women and for men was 2.45 (1.90-3.17). Hip fracture risk was lower in overweight and obese categories compared to normal weight [obese II vs normal: women 0.66 (0.55-0.80); men 0.91 (0.66-1.26)]. Further adjustment for FN BMD T-score attenuated the increased risk associated with underweight [underweight vs normal: women 1.69 (1.47-1.96); men 1.46 (1.00-2.13)]. In these models, the protective effects of overweight and obesity were attenuated, and in both sexes, the direction of association reversed to higher fracture risk in Obese II category [Obese II vs Normal: women 1.24 (0.97-1.58); men 1.70 (1.06-2.75)]. Results were similar for other fracture outcomes. Underweight is a risk factor for fracture in both men and women regardless of adjustment for BMD. However, while overweight/obesity appeared protective in base models, they became risk factors after additional adjustment for FN BMD, particularly in the Obese II category. This effect in the highest BMI categories was of greater magnitude in men than women. These results will inform the second iteration of FRAX®.
Genetic and Clinical Characterization of a Large Cohort with Suspected Monogenic Stone Disease
Cogal, Andrea G. , Ali, Ahmed E. , Arnous, Muhammad G. , Zhou, Le‐Ting , Arroyo, Jennifer, Seide, Barbara M., Reynolds, Laura M. , Kennedy, Gabrielle N. , Milliner, Dawn S. , Sas, David J. , Harris, Peter C. , Cheungpasitporn, Wisit , Tan-Arroyo, Jennifer , Alhadi, Abdulmueti , Arroyo, Jennifer , Seide, Barbara M , Rossler, Kalina J , Reynolds, Laura M , Kennedy, Gabrielle N , Elbarougy, Doaa E , Goldfarb, David S , Milliner, Dawn , Lieske, John C , Harris, Peter C , Cheungpasitporn, Wisit , Alhadi, Abdulmueti , Elbarougy, Doaa E. , Goldfarb, David S. , Lieske, John C.

Mayo Clinic

Clinical Journal of the American Society of Nephrology | August 12, 2025 | Volume: 20 | Issue: 12 | Pages: 1670-1682

10.2215/cjn.0000000817 | PMID 40794449 Get It

Key Points Genetic testing of individuals suspected of monogenic urinary stone disease resolved 34% of families with 22 different genes detected. Resolved individuals had a lower baseline and last visit eGFR and earlier age of stone presentation than the unresolved group. Specific phenotypes and younger diagnostic age were associated with a monogenic cause, allowing refinement of future screenings. Background Urinary stone disease with a clear genetic cause, monogenic stone disease (MSD), is increasingly recognized as a significant proportion of the total population. When MSD is suspected, genetic testing provides a firm diagnosis that can alter management and treatment. Here, we present testing results from a large cohort with suspected MSD. Methods Patients with features suggestive of MSD (early onset, family history, frequent stones, nephrocalcinosis [NC], and/or CKD) were recruited by the Rare Kidney Stone Consortium and genotyped for up to 160 known or candidate MSD genes via a targeted massively parallel sequencing panel. We compared clinical and biochemical features between genetically resolved MSD and unresolved individuals. Results Of 426 families (657 patients) enrolled, 145 (34%) were resolved with identified disease associated variants in 22 known MSD genes. Ninety-nine families were biallelic, 37 monoallelic, and two digenic. An additional 21 of the 231 screened family members were resolved. Genes identified in ten or more families include the following: AGXT , HOGA1 , SLC34A3 , CYP24A1 , SLC3A1 , and CLCN5 . Compared with the unresolved group, MSD probands had a lower baseline and last visit eGFR, earlier age of stone presentation, and more stone events and procedures/year of life. The resolve rate was higher in those <16 years, and NC was seen earlier in the MSD group. Overall, NC was a risk factor for lower eGFR. Among the specific disorders, patients with primary hyperoxaluria had the earliest age of stone and NC diagnosis, and as expected, the highest urinary oxalate level. Conclusions Our study emphasizes the value of selecting patients enriched for factors associated with MSD, and comprehensive genetic testing to achieve a high yield of genetic diagnoses. Significant clinical and biochemical characteristics of patients with MSD were defined. A definitive MSD diagnosis facilitates individualized management and strategies to delay disease progression in probands and affected family members.
Revealing disparities: American Indians are deferred and denied for liver transplant at a higher rate due to psychological reasons
Elmasry, Sandra , Lizaola‐Mayo, Blanca , Delafield, Nathan L. , Milam, Adam J. , Dickson, Rolland C. , Chascsa, David M. , Chascsa, David M , Lizaola-Mayo, Blanca , Milam, Adam J

Mayo Clinic

Liver Transplantation | August 12, 2025 | Volume: 32 | Issue: 2 | Pages: 278-282

10.1097/lvt.0000000000000704 | PMID 40793991 Get It